Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and placebo for the treatment of recurrent herpes labialis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medivir
• Treatments: Acyclovir; Hydrocortisone

Criteria

Inclusion Criteria:

• Generally good health

• History of recurrent herpes labialis with at last three episodes during the prior 12 months

Exclusion Criteria:

• Treatment with antivirals or immunosuppressive agents within 2 weeks prior to randomization

• Pregnant and/or nursing women

• Continuous daily treatment with pain medication

• Significant skin condition that occur in the area of herpes recurrences